{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:23:23Z","timestamp":1790101403998,"version":"4.0.1"},"reference-count":32,"publisher":"Society of Nuclear Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,8,26]]},"published-print":{"date-parts":[[2025,12]]},"DOI":"10.2967\/jnumed.125.270242","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T14:35:13Z","timestamp":1760625313000},"page":"2014-2019","source":"Crossref","is-referenced-by-count":3,"title":["PSMA PET Evaluation with a Deep Learning Platform Compared with a Standard Image Viewer and Histopathology"],"prefix":"10.2967","volume":"66","author":[{"given":"Daniel","family":"Koehler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzad","family":"Shenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivayla","family":"Apostolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Budus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Falkenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"2026030506250582000_66.12.2014.1","unstructured":"Prostate cancer. European Association of Urology website. Accessed September 19, 2025. https:\/\/uroweb.org\/guideline\/prostate-cancer\/. Accessed April 5, 2025."},{"key":"2026030506250582000_66.12.2014.2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003452"},{"key":"2026030506250582000_66.12.2014.3","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030506250582000_66.12.2014.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.198119"},{"key":"2026030506250582000_66.12.2014.5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the Prostate Cancer Molecular Imaging Standardized Evaluation framework including response evaluation for clinical trials (PROMISE v2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol."},{"key":"2026030506250582000_66.12.2014.6","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1007\/s00259-017-3725-1","article-title":"Development of standardized image interpretation for 68Ga-PSMA PET\/CT to detect prostate cancer recurrent lesions","volume":"44","author":"Fanti","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030506250582000_66.12.2014.7","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.eururo.2023.06.008","article-title":"Prostate-specific membrane antigen reporting and data system version 2.0","volume":"84","author":"Werner","year":"2023","journal-title":"Eur Urol."},{"key":"2026030506250582000_66.12.2014.8","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","article-title":"Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study","volume":"25","author":"Karpinski","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026030506250582000_66.12.2014.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.261863"},{"key":"2026030506250582000_66.12.2014.10","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00259-021-05497-8","article-title":"Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting","volume":"49","author":"Johnsson","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030506250582000_66.12.2014.11","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.euo.2024.10.011","article-title":"Treatment response assessment according to updated PROMISE criteria in patients with metastatic prostate cancer using an automated imaging platform for identification, measurement, and temporal tracking of disease","volume":"8","author":"Benitez","year":"2024","journal-title":"Eur Urol Oncol."},{"key":"2026030506250582000_66.12.2014.12","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1038\/s41598-024-53683-z","article-title":"Analytical performance validation of aPROMISE platform for prostate tumor burden, index and dominant tumor assessment with 18F-DCFPyL PET\/CT: a pilot study","volume":"14","author":"Garca Vicente","year":"2024","journal-title":"Sci Rep."},{"key":"2026030506250582000_66.12.2014.13","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1007\/s00259-024-06685-y","article-title":"Whole-body tumour burden on [18F]DCFPyL PET\/CT in biochemical recurrence of prostate cancer: association with tumour biology and PSA kinetics","volume":"51","author":"Garca-Zoghby","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030506250582000_66.12.2014.14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2024.09.010","article-title":"Patient-reported outcome measures and decision regret after prostate-specific membrane antigentargeted radioguided surgery for oligorecurrent prostate cancer","volume":"70","author":"Falkenbach","year":"2024","journal-title":"Eur Urol Open Sci."},{"key":"2026030506250582000_66.12.2014.15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.euo.2024.04.019","article-title":"Biochemical response of <0.1 ng\/mL predicts therapy-free survival of prostate cancer patients following prostate-specific membrane antigentargeted salvage surgery","volume":"8","author":"Knipper","year":"2025","journal-title":"Eur Urol Oncol."},{"key":"2026030506250582000_66.12.2014.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.263892"},{"key":"2026030506250582000_66.12.2014.17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.eururo.2022.03.002","article-title":"Robot-assisted prostate-specific membrane antigenradioguided salvage surgery in recurrent prostate cancer using a DROP-IN gamma probe: the first prospective feasibility study","volume":"82","author":"de Barros","year":"2022","journal-title":"Eur Urol."},{"key":"2026030506250582000_66.12.2014.18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2022.05.031","article-title":"Cohort study of oligorecurrent prostate cancer patients: oncological outcomes of patients treated with salvage lymph node dissection via prostate-specific membrane antigen-radioguided surgery","volume":"83","author":"Knipper","year":"2023","journal-title":"Eur Urol."},{"key":"2026030506250582000_66.12.2014.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178939"},{"key":"2026030506250582000_66.12.2014.20","doi-asserted-by":"publisher","DOI":"10.2307\/2529310"},{"key":"2026030506250582000_66.12.2014.21","unstructured":"SankeyMatic. https:\/\/sankeymatic.com\/. Accessed March 25, 2025."},{"key":"2026030506250582000_66.12.2014.22","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030506250582000_66.12.2014.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267306"},{"key":"2026030506250582000_66.12.2014.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.190827"},{"key":"2026030506250582000_66.12.2014.25","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001698"},{"key":"2026030506250582000_66.12.2014.26","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","article-title":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial","volume":"7","author":"Hope","year":"2021","journal-title":"JAMA Oncol."},{"key":"2026030506250582000_66.12.2014.27","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(90)90158-L"},{"key":"2026030506250582000_66.12.2014.28","doi-asserted-by":"crossref","first-page":"7056983","DOI":"10.1155\/2022\/7056983","article-title":"High SUVs have more robust repeatability in patients with metastatic prostate cancer: results from a prospective testretest cohort imaged with 18F-DCFPyL","volume":"2022","author":"Werner","year":"2022","journal-title":"Mol Imaging."},{"key":"2026030506250582000_66.12.2014.29","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.7150\/thno.96738","article-title":"PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: is there value beyond localization of disease?","volume":"14","author":"Kper","year":"2024","journal-title":"Theranostics."},{"key":"2026030506250582000_66.12.2014.30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.242057"},{"key":"2026030506250582000_66.12.2014.31","doi-asserted-by":"crossref","first-page":"e222010","DOI":"10.1148\/radiol.222010","article-title":"A prognostic risk score for prostate cancer based on PSMA PETderived organ-specific tumor volumes","volume":"307","author":"Seifert","year":"2023","journal-title":"Radiology."},{"key":"2026030506250582000_66.12.2014.32","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1200\/JCO.2025.43.5_suppl.15","article-title":"World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): an analysis from the X-MET collaboration [abstract]","volume":"43","author":"Tang","year":"2025","journal-title":"J Clin Oncol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:18:46Z","timestamp":1785269926000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,3]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.2967\/jnumed.125.270242"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270242","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]}}}